Lukasz Polisiakiewicz in Voorhees, New Jersey

Additional Medical Specialties Include:
INTERNAL MEDICINE

Medical School: At Still University Of Health Sciences, College Of Osteo Med, Kirksville
Graduation Year: 2011
The Primary Medical Specialty for Lukasz Polisiakiewicz is listed as: Pulmonary Disease
Approximate Years of Experience: 13
PAC (PECOS ID)#: 3577876606
NPI #: 1295033819
NPI Created On: 03/06/2011
NPI Last Updated Listed as: 04/15/2022
Primary Taxonomy Code: 207R00000X
License Number:
5101019425
Listed Gender: Male

Forms of insurance accepted by include, but are not limited to:

• Blue Cross Blue Shield
• Humana
• Oscar Garden State Insurance Corporation
• Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

1. Insertion of central venous catheter for infusion, patient 5 years or older
2. Measurement and graphic recording of total and timed exhaled air capacity
3. Measurement and graphic recording of the amount and speed of breathed air, before and following medication administration
4. Test for exercise-induced lung stress
5. Determination of lung volumes using gas dilution or washout
6. Measurement of lung diffusing capacity
7. New patient office or other outpatient visit, typically 45 minutes
8. Established patient office or other outpatient visit, typically 15 minutes
9. Established patient office or other outpatient, visit typically 25 minutes
10. Initial hospital inpatient care, typically 30 minutes per day
11. Initial hospital inpatient care, typically 50 minutes per day
12. Initial hospital inpatient care, typically 70 minutes per day
13. Subsequent hospital inpatient care, typically 15 minutes per day
14. Subsequent hospital inpatient care, typically 25 minutes per day
15. Subsequent hospital inpatient care, typically 35 minutes per day
16. Critical care delivery critically ill or injured patient, first 30-74 minutes
17. Advance care planning by the physician or other qualified health care professional
18. Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg